• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Comprehensive Characterization of Overt Myelofibrosis in an Asian Cohort: Phenotype, Mutation Landscape and Discordance Among Scoring Systems.

作者信息

Chang Yu-Sung, Wang Yu-Hung, Wei Chao-Hung, Chen Yu-Wen, Lin Hsing-Yu, Lin Chien-Chin, Tsai Xavier Cheng-Hong, Yuan Chang-Tsu, Tien Feng-Ming, Lin Yun-Chu, Lee Sze-Hwei, Kuo Yuan-Yeh, Chuang Ming-Kai, Ko Bor-Sheng, Yao Ming, Tien Hwei-Fang, Chou Wen-Chien, Hou Hsin-An

机构信息

Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.

Epigenetics of Haematopoiesis Laboratory, Division of Cancer Sciences, The University of Manchester, Manchester, UK.

出版信息

Hematol Oncol. 2025 Jan;43(1):e70040. doi: 10.1002/hon.70040.

DOI:10.1002/hon.70040
PMID:39853812
Abstract

Various prognostic scoring systems in myelofibrosis (MF) have been developed to guide clinical decision-making in MF. However, discrepancies between different scoring systems for individual patients remain poorly understood, which can result in conflicting treatment recommendations. Moreover, data regarding there applicability in Asian populations remain scarce. We conducted a retrospective analysis of patients with overt MF at National Taiwan University Hospital from November 1, 2006, to November 30, 2023. This study evaluates the distribution, concordance, and prognostic value of various scoring systems (IPSS, DIPSS, DIPSS+, MYSEC-PM, MIPSS70, MIPSS70+v2, GIPSS), focusing on the mutational landscape, particularly TP53 mutations, and cytopenic phenotypes in an Asian MF cohort. All prognostic systems effectively stratified patients by risk (p < 0.005); however, concordance between systems was low (Cohen's κ < 0.4, except for IPSS vs. DIPSS+). GIPSS demonstrated superior performance with a comparable C-index but lower Akaike and Bayesian information criterion values. Besides high-molecular risk mutations, TP53 mutations (5.2%) were associated with worse overall survival (OS) (5-year: 30% vs. 68%, p < 0.001) and a trend toward higher leukemic transformation (5-year: 22% vs. 10%, p = 0.055). Cytopenic phenotype (59%) was associated with a higher incidence of ASXL1 mutations (44% vs. 28%, p = 0.04). In multivariable analysis, elderly patients, higher-risk GIPSS, TP53 mutation and cytopenic phenotype were associated with a poorer OS. This study validated multiple prognostic scoring systems in an Asian MF cohort, with GIPSS showing superior risk stratification. Further, cytopenic phenotype and TP53 mutations were identified as independent factors linked to poorer survival.

摘要

相似文献

1
Comprehensive Characterization of Overt Myelofibrosis in an Asian Cohort: Phenotype, Mutation Landscape and Discordance Among Scoring Systems.
Hematol Oncol. 2025 Jan;43(1):e70040. doi: 10.1002/hon.70040.
2
[Analysis of prognostic factors in Chinese patients with post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis].真性红细胞增多症后骨髓纤维化和原发性血小板增多症后骨髓纤维化中国患者的预后因素分析
Zhonghua Xue Ye Xue Za Zhi. 2016 Oct 14;37(10):876-880. doi: 10.3760/cma.j.issn.0253-2727.2016.10.012.
3
Genetically inspired prognostic scoring system (GIPSS) outperforms dynamic international prognostic scoring system (DIPSS) in myelofibrosis patients.基因启发预后评分系统(GIPSS)在骨髓纤维化患者中的表现优于动态国际预后评分系统(DIPSS)。
Am J Hematol. 2019 Jan;94(1):87-92. doi: 10.1002/ajh.25335. Epub 2018 Nov 25.
4
The prognostic contribution of CBL, NRAS, KRAS, RUNX1, and TP53 mutations to mutation-enhanced international prognostic score systems (MIPSS70/plus/plus v2.0) for primary myelofibrosis.CBL、NRAS、KRAS、RUNX1 和 TP53 突变对原发性骨髓纤维化中突变增强国际预后评分系统(MIPSS70/plus/plus v2.0)的预后贡献。
Am J Hematol. 2024 Jan;99(1):68-78. doi: 10.1002/ajh.27136. Epub 2023 Oct 17.
5
Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study.原发性骨髓纤维化和真性红细胞增多症后/或原发性血小板增多症后骨髓纤维化患者接受芦可替尼治疗的临床表现、结局和预后模型的差异。一项大型多中心研究中 MYSEC-PM 的新视角。
Semin Hematol. 2018 Oct;55(4):248-255. doi: 10.1053/j.seminhematol.2018.05.013. Epub 2018 Jun 5.
6
[Evaluation of the prognostic value of MIPSS70-plus in Chinese patients with primary myelofibrosis].[MIPSS70-plus对中国原发性骨髓纤维化患者的预后价值评估]
Zhonghua Xue Ye Xue Za Zhi. 2021 Jan 14;42(1):15-20. doi: 10.3760/cma.j.issn.0253-2727.2021.01.004.
7
Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management.原发性骨髓纤维化:诊断、危险分层和治疗的 2021 年更新。
Am J Hematol. 2021 Jan;96(1):145-162. doi: 10.1002/ajh.26050. Epub 2020 Dec 2.
8
GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis.GIPSS:原发性骨髓纤维化的基因启发预后评分系统。
Leukemia. 2018 Jul;32(7):1631-1642. doi: 10.1038/s41375-018-0107-z. Epub 2018 Mar 23.
9
Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome.Ruxolitinib 在血细胞减少性骨髓纤维化中的疗效、毒性、停药和结局。
Cancer. 2023 Jun 1;129(11):1704-1713. doi: 10.1002/cncr.34722. Epub 2023 Mar 18.
10
The role of new technologies in myeloproliferative neoplasms: Application of next-generation sequencing in myelofibrosis.新技术在骨髓增殖性肿瘤中的作用:下一代测序在骨髓纤维化中的应用。
Int J Lab Hematol. 2021 Oct;43(5):1070-1077. doi: 10.1111/ijlh.13504. Epub 2021 Mar 18.